We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

6 hedge funds and large institutions have $1.05M invested in Benitec Biopharma in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

31% more capital invested

Capital invested by funds: $797K → $1.05M (+$249K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

14% less funds holding

Funds holding: 7 → 6 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$22.8K
2
Morgan Stanley
Morgan Stanley
New York
+$1.72K
3
UBS Group
UBS Group
Switzerland
+$1.29K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$6.9K
2
AIC
Ameritas Investment Company
Nebraska
-$3K

BNTC Hedge Fund Activity: Q1 2019 in Review

6 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2019, worth a combined $1.05M — up 31% from $797K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of BNTC and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $22.8K. The largest seller was Highbridge Capital Management, cutting an estimated $6.9K.

  • 6 institutional investors held Benitec Biopharma (BNTC) as of Q1 2019, down from 7 in Q4 2018.
  • Funds reported $1.05M of Benitec Biopharma stock for Q1 2019, up 31% quarter-over-quarter.
  • 0 funds opened new Benitec Biopharma positions in Q1 2019 and 1 closed out, a net change of -1 holder.
  • The largest Benitec Biopharma buyer in Q1 2019 was Susquehanna International Group, an estimated $22.8K added.
  • The largest Benitec Biopharma seller in Q1 2019 was Highbridge Capital Management, an estimated $6.9K sold.

Based on aggregated 13F filings for Q1 2019.